Prolonged granulocyte colony stimulating factor use in glycogen storage disease type 1b associated with acute myeloid leukemia and with shortened telomere length

References

• Chou JY, Jun HS, Mansfield BC. Neutropenia in type Ib glycogen storage disease. Curr Opin Hematol. 2010;17(1):36–42.
   PubMed Web of Science ®Google Scholar
• Chou JY, Jun HS, Mansfield BC. Type I glycogen storage diseases: disorders of the glucose-6-phosphatase/glucose-6-phosphate transporter complexes. J Inherit Metab Dis. 2015;38(3):511–519.
   PubMed Web of Science ®Google Scholar
• Visser G, Rake JP, Labrune P, et al. Granulocyte colony-stimulating factor in glycogen storage disease type 1b. Results of the European Study on Glycogen Storage Disease Type 1. Eur J Pediatr. 2002;1(161 Suppl):S83–S87.
   Google Scholar
• Donadieu J, Boutard P, Bernatowska E, et al. A European phase II study of recombinant human granulocyte colony-stimulating factor (lenograstim) in the treatment of severe chronic neutropenia in children. Lenograstim Study Group. Eur J Pediatr. 1997;156(9):693–700.
   PubMed Web of Science ®Google Scholar
• Dale DC, Cottle TE, Fier CJ, et al. Severe chronic neutropenia: treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry. Am J Hematol. 2003;72(2):82–93.
   PubMed Web of Science ®Google Scholar
• Rosenberg PS, Zeidler C, Bolyard AA, et al. Stable long-term risk of leukaemia in patients with severe congenital neutropenia maintained on G-CSF therapy. Br J Haematol. 2010;150(2):196–199.
   PubMed Web of Science ®Google Scholar
• Rosenberg PS, Alter BP, Bolyard AA, et al. The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. Blood 2006;107(12):4628–4635.
   PubMed Web of Science ®Google Scholar
• Kojima S, Ohara A, Tsuchida M, et al. Risk factors for evolution of acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukemia after immunosuppressive therapy in children. Blood 2002;100(3):786–790.
   PubMed Web of Science ®Google Scholar
• Socie G, Mary JY, Schrezenmeier H, et al. Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and Marrow Transplantation (EBMT). Blood 2007;109(7):2794–2796.
   PubMed Web of Science ®Google Scholar
• Locasciulli A, Arcese W, Locatelli F, et al.; Italian Aplastic Anaemia Study G. Treatment of aplastic anaemia with granulocyte-colony stimulating factor and risk of malignancy. Italian Aplastic Anaemia Study Group. Lancet. 2001;357(9249):43–44.
   PubMed Web of Science ®Google Scholar
• Gurion R, Gafter-Gvili A, Paul M, et al. Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy-systematic review and meta-analysis. Haematologica. 2009;94(5):712–719.
   PubMed Web of Science ®Google Scholar
• Pinsk M, Burzynski J, Yhap M, et al. Acute myelogenous leukemia and glycogen storage disease 1b. J Pediatr Hematol Oncol. 2002;24(9):756–758.
   PubMed Web of Science ®Google Scholar
• Schroeder T, Hildebrandt B, Mayatepek E, et al. A patient with glycogen storage disease type Ib presenting with acute myeloid leukemia (AML) bearing monosomy 7 and translocation t(3;8)(q26;q24) after 14 years of treatment with granulocyte colony-stimulating factor (G-CSF): a case report. J Med Case Rep. 2008;2:319.
   PubMedGoogle Scholar
• Simmons PS, Smithson WA, Gronert GA, et al. Acute myelogenous leukemia and malignant hyperthermia in a patient with type 1b glycogen storage disease. J Pediatr. 1984;105(3):428–431.
   PubMed Web of Science ®Google Scholar
• Chen YT, Burchell, A. Glycogen storage disease. In: Beaudet ALS, Valle D, eds. The Metabolic Basis of Inherited Disease. 2001:1521–1551.
   Google Scholar
• Kishnani PS, Austin SL, Abdenur JE, et al. Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics. Genet Med. 2014;16(11):e1.
   PubMedGoogle Scholar
• Linabery AM, Ross JA. Childhood and adolescent cancer survival in the US by race and ethnicity for the diagnostic period 1975–1999. Cancer. 2008;113(9):2575–2596.
   PubMed Web of Science ®Google Scholar
• Linabery AM, Ross JA. Trends in childhood cancer incidence in the U.S. (1992–2004). Cancer. 2008;112(2):416–432.
   PubMed Web of Science ®Google Scholar
• Pierre G, Chakupurakal G, McKiernan P, et al. Bone marrow transplantation in glycogen storage disease type 1b. J Pediatr. 2008;152(2):286–288.
   PubMed Web of Science ®Google Scholar
• Holig K, Kramer M, Kroschinsky F, et al. Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3928 donors. Blood 2009;114(18):3757–3763.
   PubMed Web of Science ®Google Scholar
• Pulsipher MA, Chitphakdithai P, Miller JP, et al. Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program. Blood 2009;113(15):3604–3611.
   PubMed Web of Science ®Google Scholar
• Hershman D, Neugut AI, Jacobson JS, et al. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst. 2007;99(3):196–205.
   PubMedGoogle Scholar
• Calderwood S, Kilpatrick L, Douglas SD, et al. Recombinant human granulocyte colony-stimulating factor therapy for patients with neutropenia and/or neutrophil dysfunction secondary to glycogen storage disease type 1b. Blood 2001;97(2):376–382.
   PubMed Web of Science ®Google Scholar
• Nuamah NM, Goker H, Kilic YA, et al. Spontaneous splenic rupture in a healthy allogeneic donor of peripheral-blood stem cell following the administration of granulocyte colony-stimulating factor (g-csf). A case report and review of the literature. Haematologica. 2006;91(5 Suppl):ECR08.
   PubMedGoogle Scholar
• Rutella S, Rumi C, Sica S, et al. Induction of T-cell mitogenic unresponsiveness by recombinant human granulocyte colony-stimulating factor (rHuG-CSF). Br J Cancer 2000;82(9):1610; author reply 1.
   PubMed Web of Science ®Google Scholar
• Rutella S, Rumi C, Pierelli L, et al. Granulocyte colony-stimulating factor perturbs lymphocyte mitochondrial function and inhibits cell cycle progression. Exp Hematol. 2000;28(6):612–625.
   PubMed Web of Science ®Google Scholar
• Hernandez JM, Castilla C, Gutierrez NC, et al. Mobilisation with G-CSF in healthy donors promotes a high but temporal deregulation of genes. Leukemia. 2005;19(6):1088–1091.
   PubMed Web of Science ®Google Scholar
• Sloand EM, Yong AS, Ramkissoon S, et al. Granulocyte colony-stimulating factor preferentially stimulates proliferation of monosomy 7 cells bearing the isoform IV receptor. Proc Natl Acad Sci U S A. 2006;103(39):14483–14488.
   PubMed Web of Science ®Google Scholar
• Germeshausen M, Welte K, Ballmaier M. In vivo expansion of cells expressing acquired CSF3R mutations in patients with severe congenital neutropenia. Blood 2009;113(3):668–670.
   PubMed Web of Science ®Google Scholar
• Tidow N, Pilz C, Teichmann B, et al. Clinical relevance of point mutations in the cytoplasmic domain of the granulocyte colony-stimulating factor receptor gene in patients with severe congenital neutropenia. Blood 1997;89(7):2369–2375.
   PubMed Web of Science ®Google Scholar
• Calado RT, Cooper JN, Padilla-Nash HM, et al. Short telomeres result in chromosomal instability in hematopoietic cells and precede malignant evolution in human aplastic anemia. Leukemia. 2012;26(4):700–707.
   PubMed Web of Science ®Google Scholar
• Dumitriu B, Feng X, Townsley DM, et al. Telomere attrition and candidate gene mutations preceding monosomy 7 in aplastic anemia. Blood 2015;125(4):706–709.
   PubMed Web of Science ®Google Scholar
• Chakraborty S, Sun CL, Francisco L, et al. Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma. J Clin Oncol. 2009;27(5):791–798.
   PubMed Web of Science ®Google Scholar
• Capraro V, Zane L, Poncet D, et al. Telomere deregulations possess cytogenetic, phenotype, and prognostic specificities in acute leukemias. Exp Hematol. 2011;39(2):195–202e2.
   PubMed Web of Science ®Google Scholar